Management, Prevention, and Safety: An Evidence Map

Scope and boundary

This chapter organizes evidence domains for research and education. It does not recommend treatment for an individual. Management decisions depend on the clinical syndrome, indication, comorbidities, hemorrhagic and ischemic risks, medications, and current specialist guidance.

The current organizing sources are the ICAAA/WSO CAA statement R009, the ESO covert cSVD guideline R062, the ESO lacunar ischemic stroke guideline R063, and the ARIA workgroup recommendations R055. Readers should follow the linked source because guidance can change and recommendation strength matters.

1. Why management evidence is hard

cSVD is heterogeneous. A trial enrolling patients with lacunar ischemic stroke answers a different question from a study of incidental WMH, probable CAA after lobar ICH, or ARIA during anti-amyloid therapy. Subgroup analyses are often underpowered, and imaging markers may modify both hemorrhagic and ischemic risk.

Every management claim should state:

Population and qualifying syndrome.
Intervention, comparator, and timing.
Primary clinical and safety outcomes.
Whether cSVD was an inclusion criterion or post-hoc subgroup.
Absolute as well as relative effects when available.
Evidence certainty and recommendation strength.
Important exclusions and competing indications.

2. Blood pressure and vascular risks

Blood-pressure control is central to general vascular prevention and is addressed across covert cSVD, lacunar stroke, and CAA guidance R009 R062 R063. The relevant question is not simply whether hypertension is associated with cSVD. It is which target, measurement strategy, time horizon, and population improve clinical outcomes without unacceptable harm.

Research distinctions include acute stroke versus long-term prevention, office versus ambulatory measurement, variability versus mean pressure, orthostatic symptoms, frailty, and interactions with cerebral autoregulation. Imaging progression can be informative, but clinical outcomes remain essential.

Smoking, physical activity, diet, sleep, diabetes management, and other vascular factors belong in the evidence map. Recommendations based on general cardiovascular benefit should be labeled differently from interventions proven specifically to alter cSVD pathology.

3. Antiplatelet therapy

Antiplatelet use depends on indication. The ESO covert cSVD guideline does not treat incidental WMH or lacunes as an automatic antiplatelet indication R062. Lacunar ischemic stroke is a secondary-prevention context addressed separately R063. Probable CAA, cSS, and prior lobar ICH raise hemorrhagic concerns that must be balanced against ischemic benefit R009 R041.

A knowledge resource should never transform the presence of a microbleed into a universal stop-or-start rule. Number, location, cSS, prior hemorrhage, cardiovascular indication, alternatives, and evidence certainty all matter.

4. Anticoagulation and competing embolic risk

CAA creates one of the field's hardest competing-risk problems: preventing cardioembolic stroke while limiting recurrent intracranial hemorrhage. Evidence may come from observational cohorts, trials that excluded the highest-risk patients, or indirect populations. Risk scores built in general atrial fibrillation populations may not capture cSS or CAA severity.

The guide should present evidence by decision context rather than issue a single rule:

Primary prevention without established embolic indication.
Atrial fibrillation after ischemic stroke.
Atrial fibrillation after lobar ICH.
Mechanical heart valve or another high-risk indication.
Consideration of nonpharmacologic alternatives.

Readers must consult current multidisciplinary guidance R009.

5. Lipid lowering

Lipid-lowering therapy has strong cardiovascular indications in many populations, while CAA-specific hemorrhagic concerns and primary-versus-secondary prevention contexts complicate interpretation. The correct evidence question includes baseline indication, prior ischemic disease, prior ICH, drug and intensity, and absolute competing risks R009 R062.

An association between low cholesterol and hemorrhage does not by itself establish that stopping a therapy improves outcomes. Confounding, reverse causation, indication, and randomized evidence must be considered.

6. Acute lacunar stroke and secondary prevention

The ESO guideline evaluates acute thrombolysis, antiplatelet treatment, blood-pressure management, progressive lacunar stroke, and longer-term prevention R063. The key conceptual point is that suspected lacunar stroke should not be denied evidence-based acute treatment solely because the lesion is small, while some cSVD-specific treatment questions remain supported by limited evidence.

The original guideline tables and evidence profiles should be used for exact recommendations and certainty. This guide summarizes the question structure, not bedside instructions.

7. CAA manifestations and inflammation

Management domains include acute ICH care, recurrence prevention, TFNEs, seizures, headache, cognitive effects, and CAA-related inflammation. CAA-ri may respond to immunosuppression, but diagnosis requires careful exclusion of mimics and specialist judgment. The 2025 statement integrates diagnostic and treatment considerations R009.

The evidence record should distinguish CAA-ri, ABRA or vasculitic pathology, spontaneous noninflammatory CAA, PRES, infection, and treatment-associated ARIA.

8. Anti-amyloid therapy and ARIA

ARIA-E refers to edema or effusion-like imaging abnormalities; ARIA-H includes microhemorrhage and superficial siderosis. Risk and monitoring depend on the specific therapy, dose schedule, APOE genotype, baseline MRI, prior hemorrhagic markers, symptoms, and timing. Spontaneous CAA-related inflammation and treatment-related ARIA share features but are not interchangeable R040 R055 R061.

A versioned ARIA record should contain:

Drug and current label or authoritative guidance date.
Baseline MRI eligibility and sequence requirements.
Surveillance schedule.
Radiographic severity definition.
Symptom assessment.
Dose-hold or discontinuation framework from the current source.
Emergency and differential considerations.
Evidence level and unresolved questions.

Because these details are treatment-specific and change over time, the website should link directly to authoritative sources rather than freeze instructions into static prose.

9. Rehabilitation and cognitive care

Rehabilitation, exercise, cognitive assessment, mood treatment, fall prevention, sleep, hearing, vision, and caregiver support can influence outcomes even when no disease-modifying vascular therapy exists. Evidence specific to cSVD phenotypes may be limited, so general stroke, dementia, and geriatric evidence should be labeled as indirect where appropriate R066 R067.

10. Trial endpoints

Potential endpoints include recurrent stroke, ICH, cognition, gait, disability, WMH progression, incident infarcts, microbleeds, diffusion measures, CVR, and fluid biomarkers. Qualification requires more than association:

Reliable acquisition and processing.
Longitudinal responsiveness.
Interpretability of change.
Prespecified relationship to clinical outcome.
Acceptable missingness and site effects.
Evidence that treatment-induced change is not an off-target artifact.

11. How the site should present management evidence

Management pages should be versioned and visually separated from disease education. Each should show population, decision, evidence date, recommendation strength, uncertainty, and source link. No page should generate patient-specific instructions or hide disagreement behind a single color-coded score.

Verification and further study

CAA diagnosis and management statement: R009
Covert cSVD guideline: R062
Lacunar ischemic stroke guideline: R063
Cardiovascular management with microbleeds or suspected CAA: R041
ARIA workgroup update: R055
WSO vascular contribution to dementia statement: R066

Sources cited in this chapter

Open the original or authoritative record to verify wording, population, methods, and limitations.